Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250350 | 1.00 | DPP4 (0.46) | DPP4KDM4EALDH1A1GAAHPGD | |
| SCHEMBL6401543 | 0.86 | KDM4E (0.54) | DPP4KDM4EALDH1A1GAAHPGD | |
| SCHEMBL5258029 | 0.81 | MAPT (0.48) | DPP4KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL5253504 | 0.81 | MAPT (0.48) | DPP4KDM4EALDH1A1HPGDNPSR1 | |
| SCHEMBL5500188 | 0.80 | KDM4E (0.55) | DPP4KDM4EALDH1A1GAAHPGD | |
| SCHEMBL1013016 | 0.79 | KDM4E (0.71) | KDM4EALDH1A1GAAHPGDNPSR1 | |
| SCHEMBL1013123 | 0.79 | KDM4E (0.71) | KDM4EALDH1A1GAAHPGDNPSR1 | |
| SCHEMBL3373962 | 0.78 | KDM4E (0.69) | DPP4KDM4EALDH1A1GAAHPGD | |
| SCHEMBL5253292 | 0.78 | ALDH1A1 (0.41) | DPP4KDM4EALDH1A1GAANPSR1 | |
| SCHEMBL5252384 | 0.78 | ALDH1A1 (0.41) | DPP4KDM4EALDH1A1GAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | BERGER DAN M | 2006-11-02 | — | — | US | claimed |
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | WYETH | 2004-06-10 | — | — | US | claimed |
| EP-1242382-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | Wyeth (US) | 2002-09-25 | — | — | EP | claimed |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | claimed |
| WO-2001047892-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-07-05 | — | — | WO | claimed |
| EP-1242382-B1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | BERGER DAN M | 2006-11-02 | — | — | US | disclosed |
| US-7105531-B2 | Tricyclic protein kinase inhibitors | WYETH (US) | 2006-09-12 | — | — | US | disclosed |
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | WYETH | 2004-06-10 | — | — | US | disclosed |
| US-6638929-B2 | Compounds containing nicotinonitrile rings; anticarcinogenic and -tumor agents; polycystic kidney disease and colonic polyps; antiproliferative agents; angiogenesis inhibitors; restenosis; atherosclerosis; angiofibromas; hemangiomas; | WYETH | 2003-10-28 | — | — | US | disclosed |
| EP-1242382-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | Wyeth (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001047892-A1 | TRICYCLIC PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110762-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | DPP4 3832/4885KDM4E 1644/4885ALDH1A1 3285/4885 |
| US-20060247217-A1 | Tricyclic protein kinase inhibitors | CDK1, CDKN1A, CDK2 | DPP4 3709/4885KDM4E 1432/4885ALDH1A1 3511/4885 |
| US-20010051620-A1 | Tricyclic protein kinase inhibitors | CDK1, CHEK1, ABL1 | DPP4 2895/4885KDM4E 1527/4885ALDH1A1 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.